PBYI — Puma Biotechnology Income Statement
0.000.00%
Last trade - 00:00- $148.83m
- $114.92m
- $230.47m
- 77
- 96
- 88
- 99
Annual income statement for Puma Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 225 | 253 | 228 | 236 | 230 |
| Cost of Revenue | |||||
| Gross Profit | 186 | 189 | 173 | 173 | 166 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 272 | 270 | 217 | 203 | 200 |
| Operating Profit | -46.6 | -16.4 | 11.3 | 32.6 | 31 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -59.8 | -28.8 | 0.457 | 22.7 | 24.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -60 | -29.1 | 0.002 | 21.6 | 30.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -60 | -29.1 | 0.002 | 21.6 | 30.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -60 | -29.1 | 0.002 | 21.6 | 30.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.25 | -0.433 | 0.18 | 0.467 | 0.617 |